2024
Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftmentEfgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial
Jacobs J, Booth G, Stephens L, Tormey C, Adkins B. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. The Lancet 2024, 404: 433. PMID: 39097393, DOI: 10.1016/s0140-6736(24)01264-9.Peer-Reviewed Original ResearchA multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019
2022
Alloimmunization following antigen‐negative red blood cell transfusion
Jacobs J, Binns T, Abels E, Iyer K, Villalba C, Verma A, Sostin N, Tormey C. Alloimmunization following antigen‐negative red blood cell transfusion. Transfusion 2022, 63: 430-434. PMID: 36458330, DOI: 10.1111/trf.17208.Peer-Reviewed Case Reports and Technical NotesConceptsTransfusion of RBCsRed blood cell transfusionRed blood cell alloimmunizationPrevious antigen exposureBlood cell transfusionAlloantibody specificitiesCell transfusionRBC transfusionAntigen exposureRBC alloantibodiesAntigenic stimulusDetectable titersAntigenic stimulationMyeloid neoplasmsTransfusionAlloantibodiesAlloimmunizationParticular antigenPrior exposureStimulatory eventsExact mechanismCorresponding antibodiesRBCsExposurePregnancyAssessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis
Kerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, PMCID: PMC11472026, DOI: 10.1111/trf.17136.Peer-Reviewed Original ResearchConceptsAcinetobacter calcoaceticus-baumannii complexBlood productsS. saprophyticusPlatelet unitsContaminated blood productsCDC investigationsApheresis platelet productsTransfusion reactionsPolymicrobial contaminationPlatelet productsDisease controlBacterial isolatesStudy designStaphylococcus saprophyticusPolymicrobial interactionsCDC casesSaprophyticusFuture studiesPotential interactionsCommon sourceSepsisIsolatesCasesCoaggregationProcuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure
Rodriguez J, Tormey C. Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure. Immunohematology 2022, 38: 96-99. PMID: 36190197, DOI: 10.21307/immunohematology-2022-049.Peer-Reviewed Case Reports and Technical NotesConceptsAmerican Rare Donor ProgramRed blood cell unitsAntigen-positive unitsLife-saving procedurePotential clinical significanceMultiple comorbiditiesKnee amputationExtremity amputationCritical anemiaCase reportAdverse reactionsClinical significanceCell unitsPatient plasmaTransfusion communityGroup OClinical necessityDonor ProgramRBC unitsPatientsAmputationCompatible unitsAnemiaChallenging caseRare eventAssociation of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBloodCan transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortalityEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor
Jacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. Journal Of Clinical Apheresis 2021, 37: 316-319. PMID: 34953078, DOI: 10.1002/jca.21962.Peer-Reviewed Original ResearchConceptsCellular therapy productsHematopoietic stem cellsAllogeneic blood productsAutologous hematopoietic stem cellsHematopoietic stem cell productsPathogenic Gram-negative organismsNormal skin floraTherapy productsCase of SalmonellaStem cell productsGram-negative organismsAsymptomatic donorsTherapeutic dilemmaBlood productsPathogen reduction technologySkin floraHSC productsAdverse effectsCell productsPrior reportsSignificant reductionStem cellsSalmonellosisSalmonella bacteriaMost microorganismsRBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?
Lee ES, Hendrickson JE, Tormey CA. RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary? Transfusion 2021, 61: 3283-3285. PMID: 34767268, DOI: 10.1111/trf.16736.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationTherapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients
Olsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeSmall fiber neuropathyAdverse eventsPlasma exchangeLower extremity paresthesiasSymptomatic response rateAutoantibody-mediated disorderSkin biopsy resultsSFN symptomsTS-HDSExtremity paresthesiasPeripheral neuropathySymptomatic improvementCase seriesIgM antibodiesMean ageTPE proceduresBiopsy resultsTreatment optionsDisease progressionIgM classVasovagal reactionsClose monitoringLaboratory confirmationResponse rateDevelopment of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene
Manrai PA, Siddon AJ, Hager KM, Hendrickson JE, Keller MA, Tormey CA. Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene. Immunohematology 2021, 37: 109-112. PMID: 34591379, DOI: 10.21307/immunohematology-2021-015.Peer-Reviewed Original ResearchConceptsHigh-prevalence antigenReagent red blood cellsDirect antiglobulin testBlood samplesBlood group APatient blood samplesImmunohematology reference laboratoryRare alloantibodyRed blood cellsOncologic careAntiglobulin testGroup APolynesian descentBlood cellsNon-conservative amino acid changeSingle nucleotide variantsReference laboratoryAmino acid changesFamilial backgroundExon 8Antigen expressionExon 7Nucleotide variantsAcid changesExon 4Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola‐Visner M, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Study‐IV‐Pediatric F. Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2021, 61: 2589-2600. PMID: 34455598, DOI: 10.1111/trf.16626.Peer-Reviewed Original ResearchConceptsInternational normalized ratioBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIINational Heart LungTransfusion practicePediatric oncologyRecipient EpidemiologyHSCT patientsPlasma transfusionRed blood cellsPlatelet countHeart LungHematopoietic stem cell transplantation patientsHematopoietic stem cell transplant patientsMedian international normalized ratioStem cell transplant patientsStem cell transplantation patientsLower INR valuesPre-transfusion HbMedian platelet countMulticenter retrospective studyCell transplant patientsCell transplantation patientsStudy IIIAcute myeloid leukemiaEarly but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseClinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future
Cornish NE, Anderson NL, Arambula DG, Arduino MJ, Bryan A, Burton NC, Chen B, Dickson BA, Giri JG, Griffith NK, Pentella MA, Salerno RM, Sandhu P, Snyder JW, Tormey CA, Wagar EA, Weirich EG, Campbell S. Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future. Clinical Microbiology Reviews 2021, 34: 10.1128/cmr.00126-18. PMID: 34105993, PMCID: PMC8262806, DOI: 10.1128/cmr.00126-18.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClinical laboratoriesPatient specimensPersonal protective equipmentHospital clinical laboratoriesPatient deathInfectious disease outbreaksInfectious agentsReliable laboratory testingBiocontainment unitPatient careTest utilizationOngoing outbreakProtective equipmentClinical laboratory professionalsAnatomic pathologySpecimen collectionEbola outbreakPublic healthLaboratory professionalsImportance of biosafetyPast outbreaksOutbreakLaboratory testingDisease outbreaksCompetency assessmentCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agentsDe novo acquired hemophilia as an immune dysregulation phenomenon following SARS‐CoV‐2 infection
Olsen GM, Rinder HM, Tormey CA. De novo acquired hemophilia as an immune dysregulation phenomenon following SARS‐CoV‐2 infection. Transfusion 2021, 61: 989-991. PMID: 33368293, DOI: 10.1111/trf.16254.Peer-Reviewed Original Research
2020
Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn
Gupta GK, Balbuena-Merle R, Hendrickson JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion And Apheresis Science 2020, 59: 102946. PMID: 32962917, DOI: 10.1016/j.transci.2020.102946.Peer-Reviewed Original ResearchConceptsRed blood cellsHemolytic diseaseCurrent pathophysiologic mechanismsSetting of pregnancyPeri-partum periodPregnant patientsRBC alloantibodiesPathophysiologic mechanismsTransfusion practiceAlloantibody detectionTransfusion therapyClinical impactAlloimmunizationTransfusion communityBlood bankPregnancyDeadliest formBlood cellsAlloantibodiesFetusesDiseaseLaboratory toolPatientsTherapySettingPatient monitoring during transfusion: Does computerization hold the key to improving an age‐old practice?
Gehrie EA, Tormey CA. Patient monitoring during transfusion: Does computerization hold the key to improving an age‐old practice? Transfusion 2020, 60: 1888-1890. PMID: 33460168, DOI: 10.1111/trf.16030.Peer-Reviewed Original Research